Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (OP: ESAIY ) 10.37 -0.05 (-0.48%) Streaming Delayed Price Updated: 3:54 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about ESAIY < Previous 1 2 Next > Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal August 24, 2024 Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... Via Talk Markets Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement August 22, 2024 The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... Via Benzinga Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED August 17, 2024 Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... Via Talk Markets Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug July 26, 2024 Biogen partner Eisai is planning to ask European regulators to re-examine their decision. Via Investor's Business Daily The 3 Best Neuroscience Biotech Stocks to Buy Now July 19, 2024 Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now. Via InvestorPlace Current Analysis: Eisai Co Ltd (ESAIY) July 16, 2023 Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price. Via Talk Markets Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... Via Talk Markets 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. Via InvestorPlace Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst July 03, 2024 The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... Via Benzinga Exposures Product Safety Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai July 02, 2024 The company is on deck to rival Biogen and Eisai's Leqembi. Via Investor's Business Daily Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst June 11, 2024 Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. Via Benzinga Exposures Product Safety Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win June 11, 2024 An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. Via Investor's Business Daily Exposures Product Safety Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug June 10, 2024 The FDA isn't bound by the committee's recommendation, but often follows it. Via Investor's Business Daily Exposures Product Safety The 3 Most Undervalued Pharma Stocks to Buy in June 2024 June 06, 2024 These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. Via InvestorPlace Topics Economy Exposures Economy Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment May 15, 2024 The company is hoping to launch an under-the-skin version of its infusion, Leqembi. Via Investor's Business Daily Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline? April 24, 2024 Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares? Via Investor's Business Daily Topics Earnings Exposures Financial 3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition April 11, 2024 Wall Street often ignores the stocks of companies with huge potential. Here are three overlooked stocks to buy. Via InvestorPlace Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. Via Investor's Business Daily Exposures Product Safety 3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good February 12, 2024 For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks. Via InvestorPlace Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million February 11, 2024 I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China... Via Talk Markets Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs January 23, 2024 These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. Via InvestorPlace Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 3 Aging Population Stocks to Profit from the Boomer Generation December 21, 2023 The elderly population of the U.S. is expected to grow tremendously in the coming years. Here are three stocks to buy for an aging population. Via InvestorPlace Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others November 21, 2023 Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this Via Benzinga Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning November 17, 2023 Biotech companies are edging closer to finding the answers behind Alzheimer's disease. Via Investor's Business Daily 3 Biotech Moonshots to Bet on the Future of Health November 06, 2023 Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property The 3 Best Biotech Stocks to Buy Now: September 2023 September 04, 2023 With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. Via InvestorPlace 3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes July 30, 2023 Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. Via InvestorPlace All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings July 24, 2023 Analysts expect Biogen to report a a decline in both profits and sales in Q2. Via Investor's Business Daily Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move July 07, 2023 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.